KemPharm Stock Forecast, Price & News

+0.21 (+2.08 %)
(As of 08/2/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume342,377 shs
Average Volume2.36 million shs
Market Capitalization$349.11 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive KMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for KemPharm and its competitors with MarketBeat's FREE daily newsletter.

KemPharm logo

About KemPharm

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia. KemPharm's lead clinical development candidate for the treatment of stimulant use disorder, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. The company was incorporated in 2006 and is headquartered in Celebration, Florida.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.77 out of 5 stars

Medical Sector

819th out of 2,226 stocks

Pharmaceutical Preparations Industry

403rd out of 870 stocks

Analyst Opinion: 2.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

KemPharm (NASDAQ:KMPH) Frequently Asked Questions

Is KemPharm a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for KemPharm in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KemPharm stock.
View analyst ratings for KemPharm
or view top-rated stocks.

What stocks does MarketBeat like better than KemPharm?

Wall Street analysts have given KemPharm a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but KemPharm wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is KemPharm's next earnings date?

KemPharm is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for KemPharm

How were KemPharm's earnings last quarter?

KemPharm, Inc. (NASDAQ:KMPH) issued its quarterly earnings results on Thursday, May, 13th. The specialty pharmaceutical company reported ($1.61) EPS for the quarter, missing the consensus estimate of ($0.17) by $1.44. The specialty pharmaceutical company earned $12.12 million during the quarter, compared to analysts' expectations of $2.10 million.
View KemPharm's earnings history

How has KemPharm's stock price been impacted by COVID-19?

KemPharm's stock was trading at $0.2452 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KMPH shares have increased by 4,100.7% and is now trading at $10.30.
View which stocks have been most impacted by COVID-19

What price target have analysts set for KMPH?

2 equities research analysts have issued 1-year price objectives for KemPharm's shares. Their forecasts range from $12.00 to $12.00. On average, they expect KemPharm's stock price to reach $12.00 in the next year. This suggests a possible upside of 16.5% from the stock's current price.
View analysts' price targets for KemPharm
or view top-rated stocks among Wall Street analysts.

Who are KemPharm's key executives?

KemPharm's management team includes the following people:
  • Dr. Travis C. Mickle, Co-Founder, Chairman, Pres & CEO (Age 48, Pay $833.6k)
  • Mr. R. LaDuane Clifton CPA, CFO, Sec. & Treasurer (Age 49, Pay $489.92k)
  • Dr. Sven Guenther, Exec. VP of R&D (Age 49, Pay $522.14k)
  • Ms. Christal M. M. Mickle, Co-Founder and VP of Operations & Product Devel. (Age 42)
  • Mr. Timothy J. Sangiovanni CPA, VP & Corp. Controller (Age 37)
  • Dr. Andrew Barrett, VP of Scientific Affairs

Who are some of KemPharm's key competitors?

What other stocks do shareholders of KemPharm own?

When did KemPharm IPO?

(KMPH) raised $60 million in an initial public offering on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

What is KemPharm's stock symbol?

KemPharm trades on the NASDAQ under the ticker symbol "KMPH."

Who are KemPharm's major shareholders?

KemPharm's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Kovack Advisors Inc. (0.18%), New York State Common Retirement Fund (0.07%), Alliancebernstein L.P. (0.07%) and Cutler Group LP (0.00%). Company insiders that own KemPharm stock include Gordon K Johnson, R Laduane Clifton, Richard W Pascoe, Samuel J Braun, Timothy J Sangiovanni and Travis C Mickle.
View institutional ownership trends for KemPharm

Which institutional investors are selling KemPharm stock?

KMPH stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for KemPharm
or view top insider-selling stocks.

Which institutional investors are buying KemPharm stock?

KMPH stock was bought by a variety of institutional investors in the last quarter, including Kovack Advisors Inc., New York State Common Retirement Fund, and Alliancebernstein L.P.. Company insiders that have bought KemPharm stock in the last two years include Gordon K Johnson, R Laduane Clifton, Richard W Pascoe, Samuel J Braun, Timothy J Sangiovanni, and Travis C Mickle.
View insider buying and selling activity for KemPharm
or or view top insider-buying stocks.

How do I buy shares of KemPharm?

Shares of KMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is KemPharm's stock price today?

One share of KMPH stock can currently be purchased for approximately $10.30.

How much money does KemPharm make?

KemPharm has a market capitalization of $349.11 million and generates $13.29 million in revenue each year. The specialty pharmaceutical company earns $-12,760,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis.

How many employees does KemPharm have?

KemPharm employs 22 workers across the globe.

What is KemPharm's official website?

The official website for KemPharm is

Where are KemPharm's headquarters?

KemPharm is headquartered at 1180 Celebration Boulevard Suite 103, Celebration FL, 34747.

How can I contact KemPharm?

KemPharm's mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The specialty pharmaceutical company can be reached via phone at 321-939-3416 or via email at [email protected]

This page was last updated on 8/2/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.